18+ · Research Use Only · Not for Human Consumption
Regulatory Status Tracker
Approved where, and for what.
As of 23 September 2026, this tracker records the status of each research compound in the Primara Labs catalogue with FDA Philippines, the US Food and Drug Administration and the European Medicines Agency, each read from the authority's own database or the sponsor's own statement. An approval applies to a named medicine for a named indication; it never makes a research vial an approved product.
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
All compounds
Status by authority
| Retatrutide | Not established | Investigational | No record found | Sponsor plans a US Biologics License Application submission in Q1 2027 |
| Tirzepatide | Not established | Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound) | Approved for type 2 diabetes mellitus and weight management (Mounjaro) | None published |
| Semaglutide | Not established | Approved for glycemic control in type 2 diabetes mellitus and related cardiovascular and kidney risk reduction (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in obesity or overweight (Wegovy) | Approved for type 2 diabetes mellitus (Ozempic, Rybelsus), weight management (Wegovy) and non-cirrhotic MASH with F2 to F3 fibrosis (Kayshild) | None published |
| BPC-157 | Not established | No record found | No record found | None published |
| TB-500 (thymosin beta-4) | Not established | No record found | No record found | None published |
| GHK-Cu (copper tripeptide-1) | Not established | No record found | No record found | None published |
| KPV | Not established | No record found | No record found | None published |
| NAD+ (nicotinamide adenine dinucleotide) | Not established | No record found | No record found | None published |
| MOTS-c | Not established | No record found | No record found | None published |
| Tesamorelin | Not established | Approved for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy | Not approved | None published |
| CJC-1295 | Not established | No record found | No record found | None published |
| Ipamorelin | Not established | No record found | No record found | None published |
| Bremelanotide (PT-141) | Not established | Approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women | No record found | None published |
| Semax | Not established | No record found | No record found | None published |
| Selank | Not established | No record found | No record found | None published |
| DSIP (delta sleep-inducing peptide) | Not established | No record found | No record found | None published |
Metabolic
Is Retatrutide approved in the Philippines?
Retatrutide: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "Investigational". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- Investigational
- Eli Lilly's release of 23 July 2026 describes retatrutide as investigational. Drugs@FDA returned no approved application.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Sponsor plans a US Biologics License Application submission in Q1 2027
- Eli Lilly press release dated 23 July 2026.
- Source · checked 23 September 2026
Metabolic
Is Tirzepatide approved in the Philippines?
Tirzepatide: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound)". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound)
- Drugs@FDA: Mounjaro (NDA215866, approved 13 May 2022); Zepbound (NDA217806, approved 8 November 2023). The approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.
- Source · checked 23 September 2026
- EMA
- Approved for type 2 diabetes mellitus and weight management (Mounjaro)
- Mounjaro, EMEA/H/C/005620, authorised 15 September 2022. The authorisation covers the named medicine only.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- None sought: an approved medicine already exists.
- Not published
Metabolic
Is Semaglutide approved in the Philippines?
Semaglutide: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "Approved for glycemic control in type 2 diabetes mellitus and related cardiovascular and kidney risk reduction (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in obesity or overweight (Wegovy)". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- Approved for glycemic control in type 2 diabetes mellitus and related cardiovascular and kidney risk reduction (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in obesity or overweight (Wegovy)
- Drugs@FDA: Ozempic (NDA209637, approved 5 December 2017); WEGOVY (injection) (NDA215256, approved 4 June 2021); RYBELSUS / OZEMPIC (tablets) (NDA213051, approved 20 September 2019); Rybelsus (NDA213182, approved 16 January 2020); WEGOVY (tablets) (NDA218316, approved 22 December 2025). The approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.
- Source · checked 23 September 2026
- EMA
- Approved for type 2 diabetes mellitus (Ozempic, Rybelsus), weight management (Wegovy) and non-cirrhotic MASH with F2 to F3 fibrosis (Kayshild)
- Five authorised products containing semaglutide, all held by Novo Nordisk A/S. The authorisation covers the named medicines only.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- None sought: an approved medicine already exists.
- Not published
Tissue repair
Is BPC-157 approved in the Philippines?
BPC-157: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Tissue repair
Is TB-500 approved in the Philippines?
TB-500: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Tissue repair
Is GHK-Cu approved in the Philippines?
GHK-Cu: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Tissue repair
Is KPV approved in the Philippines?
KPV: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Cellular
Is NAD+ approved in the Philippines?
NAD+: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Cellular
Is MOTS-c approved in the Philippines?
MOTS-c: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Growth hormone axis
Is Tesamorelin approved in the Philippines?
Tesamorelin: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "Approved for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- Approved for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy
- Drugs@FDA: Egrifta (BLA022505, approved 10 November 2010). The approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.
- Source · checked 23 September 2026
- EMA
- Not approved
- The application for Egrifta (EMEA/H/C/002427) was withdrawn on 21 June 2012; no marketing authorisation was granted.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- None sought: an approved medicine already exists.
- Not published
Growth hormone axis
Is CJC-1295 approved in the Philippines?
CJC-1295: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Growth hormone axis
Is Ipamorelin approved in the Philippines?
Ipamorelin: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Melanocortin
Is Bremelanotide approved in the Philippines?
Bremelanotide: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "Approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- Approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
- Drugs@FDA: Vyleesi (NDA210557, approved 21 June 2019). The approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- None sought: an approved medicine already exists.
- Not published
Neuropeptide
Is Semax approved in the Philippines?
Semax: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Neuropeptide
Is Selank approved in the Philippines?
Selank: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
Neuropeptide
Is DSIP approved in the Philippines?
DSIP: FDA Philippines status not established (Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.); US FDA "No record found". Checked 23 September 2026.
- FDA Philippines
- Not established
- Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.
- Not published
- US FDA
- No record found
- Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
- Source · checked 23 September 2026
- EMA
- No record found
- No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
- Source · checked 23 September 2026
- Sponsor's next milestone
- Not established
- No sponsor identified in any record read.
- Not published
FDA Philippines
Advisories naming these compounds
| Advisory | Date | Compounds | Summary |
|---|---|---|---|
| FDA Advisory No. 2026-0814 | 2026-07-30 | Tirzepatide | FDA Philippines warned the public against buying or using an unregistered tirzepatide product sold as Tirz Laine Tirzepatide 30mg/3 mL, which had not been issued a Certificate of Product Registration. |
| FDA Advisory No. 2026-1019 | 2026-09-04 | Tirzepatide | FDA Philippines warned the public against buying or using an unregistered tirzepatide product sold as Peptatide Tirzepatide 15mg with a bacteriostatic water kit, which had not been issued a Certificate of Product Registration. |
| FDA Advisory No. 2025-1200 | 2025-11-06 | Semaglutide | FDA Philippines published updates to its list of VAT-exempt health products under the CREATE Act, including seven semaglutide solutions for injection listed under drugs for diabetes. |
Method
How statuses are recorded
Methodology
Values are exactly one of "Not approved", "Approved for" a named indication, "Investigational" or "No record found". "No record found" means the authority's database was searched and returned nothing; a status that could not be read is shown as "Not established" with the reason.
US FDA statuses come from Drugs@FDA and the FDA label; EMA statuses from the EMA medicines data; FDA Philippines from its own registration records and advisories.
Cite this
Primara Labs Research Desk, "Regulatory status of research peptides", last updated 23 September 2026, https://www.primaralabs.com/research/status